Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Sarcoma 1

Conditions

Glioblastoma 2Neoplasms 1Gliosarcoma 1Brain Neoplasms 1

Interventions

Temozolomide 39Radiotherapy 18Lomustine 12Bevacizumab 11Carmustine 8Radiation 7Procarbazine 4Magnetic Resonance Spectroscopy 4Surgical Procedures, Operative 3pembrolizumab 2depatuxizumab mafodotin 2Tf-CRM107 2Specimen Handling 2Radiotherapy, Intensity-Modulated 2Drug Therapy 2Dihematoporphyrin Ether 2DNA Methylation 2Carboplatin 2ABT-414 2trans-sodium crocetinate 1tofacitinib 1sargramostim 1rindopepimut 1niraparib 1marizomib 1enzastaurin 1edotecarin 1contrast agent BR1 1cediranib 1carmustine, poliferprosan 20 drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Glioblastoma × ABT-414 × Clear all
NCT02573324 2023-05-11

Intellance1

AbbVie

Phase 3 Completed
691 enrolled 28 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT03419403 2021-04-14

UNITE Study: Understanding New Interventions With GBM ThErapy

AbbVie

Phase 3 Terminated
40 enrolled 16 charts
CNS

Glioblastoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡